Intussusception risk after rotavirus vaccination in U.S. infants.

BACKGROUND International postlicensure studies have identified an increased risk of intussusception after vaccination with the second-generation rotavirus vaccines RotaTeq (RV5, a pentavalent vaccine) and Rotarix (RV1, a monovalent vaccine). We studied this association among infants in the United States. METHODS The study included data from infants 5.0 to 36.9 weeks of age who were enrolled in three U.S. health plans that participate in the Mini-Sentinel program sponsored by the Food and Drug Administration. Potential cases of intussusception and vaccine exposures from 2004 through mid-2011 were identified through procedural and diagnostic codes. Medical records were reviewed to confirm the occurrence of intussusception and the status with respect to rotavirus vaccination. The primary analysis used a self-controlled risk-interval design that included only vaccinated children. The secondary analysis used a cohort design that included exposed and unexposed person-time. RESULTS The analyses included 507,874 first doses and 1,277,556 total doses of RV5 and 53,638 first doses and 103,098 total doses of RV1. The statistical power for the analysis of RV1 was lower than that for the analysis of RV5. The number of excess cases of intussusception per 100,000 recipients of the first dose of RV5 was significantly elevated, both in the primary analysis (attributable risk, 1.1 [95% confidence interval, 0.3 to 2.7] for the 7-day risk window and 1.5 [95% CI, 0.2 to 3.2] for the 21-day risk window) and in the secondary analysis (attributable risk, 1.2 [95% CI, 0.2 to 3.2] for the 21-day risk window). No significant increase in risk was seen after dose 2 or 3. The results with respect to the primary analysis of RV1 were not significant, but the secondary analysis showed a significant risk after dose 2. CONCLUSIONS RV5 was associated with approximately 1.5 (95% CI, 0.2 to 3.2) excess cases of intussusception per 100,000 recipients of the first dose. The secondary analysis of RV1 suggested a potential risk, although the study of RV1 was underpowered. These risks must be considered in light of the demonstrated benefits of rotavirus vaccination. (Funded by the Food and Drug Administration.).

[1]  Benjamin A Lopman,et al.  Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data , 2011, The Pediatric infectious disease journal.

[2]  Cecile Viboud,et al.  Trends in Intussusception Hospitalizations Among US Infants, 1993–2004: Implications for Monitoring the Safety of the New Rotavirus Vaccination Program , 2008, Pediatrics.

[3]  J. Stockman.  Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil , 2013 .

[4]  J. Loughlin,et al.  Postmarketing Evaluation of the Short-term Safety of the Pentavalent Rotavirus Vaccine , 2012, The Pediatric infectious disease journal.

[5]  M. Kolczak,et al.  Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. , 2006, Journal of clinical epidemiology.

[6]  K. Soares-Weiser,et al.  Vaccines for preventing rotavirus diarrhoea: vaccines in use. , 2019, The Cochrane database of systematic reviews.

[7]  J. Bines,et al.  Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. , 2004, Vaccine.

[8]  I. Kassis,et al.  An Outbreak of Mycobacterium mucogenicum Bacteremia in Pediatric Hematology-oncology Patients , 2011, The Pediatric infectious disease journal.

[9]  K. Ariyoshi,et al.  Association Between Nasopharyngeal Load of Streptococcus pneumoniae, Viral Coinfection, and Radiologically Confirmed Pneumonia in Vietnamese Children , 2011, The Pediatric infectious disease journal.

[10]  Katherine J. Lee,et al.  Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Manish M Patel,et al.  Decline in Rotavirus Hospitalizations and Health Care Visits for Childhood Diarrhea Following Rotavirus Vaccination in El Salvador , 2011, The Pediatric infectious disease journal.

[12]  K. Krishnamoorthy,et al.  New approximate confidence intervals for the difference between two Poisson means and comparison , 2013 .

[13]  Marsha A Raebel,et al.  Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.

[14]  S. Lambert,et al.  Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule , 2011, The Pediatric infectious disease journal.

[15]  L. J. Van Marter.  Risk of Intussusception Following Administration of a Pentavalent Rotavirus Vaccine in US Infants , 2012 .

[16]  M. Kulldorff.  A spatial scan statistic , 1997 .

[17]  Katherine J. Lee,et al.  Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. , 2011, Vaccine.

[18]  E. Lewis,et al.  Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization , 2010, The Pediatric infectious disease journal.

[19]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[20]  Manish M Patel,et al.  Real-world impact of rotavirus vaccination. , 2011, The Pediatric infectious disease journal.

[21]  John P. Mullooly,et al.  Comparison of epidemiologic methods for active surveillance of vaccine safety. , 2008, Vaccine.

[22]  Michael Haber,et al.  Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006–2012 , 2013, Pediatrics.

[23]  Manish M Patel,et al.  Sustained Decline in Rotavirus Detections in the United States Following the Introduction of Rotavirus Vaccine in 2006 , 2011, The Pediatric infectious disease journal.

[24]  Richard Platt,et al.  Design of a National Distributed Health Data Network , 2009, Annals of Internal Medicine.

[25]  J P Mullooly,et al.  Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team. , 2000, Archives of family medicine.

[26]  W Katherine Yih,et al.  Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine , 2010, The Pediatric infectious disease journal.

[27]  T. Breuer,et al.  Postmarketing Surveillance of Intussusception Following Mass Introduction of the Attenuated Human Rotavirus Vaccine in Mexico , 2012, The Pediatric infectious disease journal.

[28]  Michael Nguyen,et al.  The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise , 2012, Pharmacoepidemiology and drug safety.

[29]  Richard Platt,et al.  The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.

[30]  Manish M Patel,et al.  Effect of Rotavirus Vaccine on Diarrhea Mortality in Different Socioeconomic Regions of Mexico , 2013, Pediatrics.

[31]  Manish M Patel,et al.  Reduction of Diarrhea-associated Hospitalizations Among Children Aged <5 Years in Panama Following the Introduction of Rotavirus Vaccine , 2011, The Pediatric infectious disease journal.

[32]  Manish M Patel,et al.  Postlicensure Monitoring of Intussusception After RotaTeq Vaccination in the United States, February 1, 2006, to September 25, 2007 , 2008, Pediatrics.

[33]  Manish M Patel,et al.  Impact of Rotavirus Vaccination on Diarrhea-related Hospitalizations Among Children <5 Years of Age in Mexico , 2011, The Pediatric infectious disease journal.